诺和诺德跌倒，竞争对手能“吃饱”吗？礼来、安进等股小幅走高_老虎社区_美港股上老虎

诺和诺德跌倒，竞争对手能“吃饱”吗？礼来、安进等股小幅走高

老虎资讯综合12-20 23:14

诺和诺德周五公布了一项名为REDEFINE 1的三期临床试验的主要结果。在评估所有人都坚持治疗的治疗效果时，使用CagriSema治疗的患者在68周后体重减轻22.7%，低于市场预期的25%。诺和诺德股价仍跌超19%，跌幅有所收窄。

诺和诺德的竞争对手方面，截至发稿礼来涨4.6%，Viking Therapeutics涨3.6%，安进涨超1%。

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

暂无评论

热议股票

7x24

全部

关于我们·老虎社区守则·老虎社区账号管理规范·老虎社区服务协议·老虎社区隐私政策

公司名称：北京至简风宜信息技术有限公司

违法和不良信息投诉：010-5681-3562（工作时间9:30-18:30）

邮箱：service@laohu8.com

营业执照：91110105MA01A4U55R

ICP备：京ICP备18016422号

网安备：京公网安备11010502036490

关注我们

{"i18n":{"language":"zh_CN"},"data":{"share":"https://www.laohu8.com/m/news/1151227836?lang=zh_CN&edition=full","thumbnail":"https://static.tigerbbs.com/64d7f8b1a0687a6bf124201afc1b1baa","is_english":false,"pubTime":"2024-12-20 23:14","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1151227836","market":"us","top_or_hot":-1,"title":"诺和诺德跌倒，竞争对手能“吃饱”吗？礼来、安进等股小幅走高","media":"老虎资讯综合","content":"<html><head></head><body><p>诺和诺德周五公布了一项名为REDEFINE 1的三期临床试验的主要结果。在评估所有人都坚持治疗的治疗效果时，使用CagriSema治疗的患者在68周后体重减轻22.7%，低于市场预期的25%。诺和诺德股价仍跌超19%，跌幅有所收窄。</p><p></p><p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/a588761a6ecb24cca162b2033802c061\" tg-width=\"560\" tg-height=\"240\"/></p><p>诺和诺德的竞争对手方面，截至发稿礼来涨4.6%，Viking Therapeutics涨3.6%，安进涨超1%。</p><p></p><p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/c990dc44923ea6ee3a981a8af89de3e1\" tg-width=\"560\" tg-height=\"240\"/></p><p></p><p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/09a011ca446a30b972a87f95e9d16c14\" tg-width=\"560\" tg-height=\"240\"/></p><p></p><p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/b6d6474cf90562ddfeca683df34fc417\" tg-width=\"560\" tg-height=\"240\"/></p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>诺和诺德跌倒，竞争对手能“吃饱”吗？礼来、安进等股小幅走高</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n诺和诺德跌倒，竞争对手能“吃饱”吗？礼来、安进等股小幅走高\n</h2>\n\n<h4 class=\"meta\">\n\n2024-12-20 23:14 北京时间&nbsp;&nbsp;&nbsp;<strong>老虎资讯综合</strong>\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>诺和诺德周五公布了一项名为REDEFINE 1的三期临床试验的主要结果。在评估所有人都坚持治疗的治疗效果时，使用CagriSema治疗的患者在68周后体重减轻22.7%，低于市场预期的25%。诺和诺德股价仍跌超19%，跌幅有所收窄。诺和诺德的竞争对手方面，截至发稿礼来涨4.6%，Viking Therapeutics涨3.6%，安进涨超1%。</p>\n\n<a href=\"\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"AMGN","symbol_name":"安进","start_time":0,"source_url":"","article_id":"1151227836","we_media_id":"102","thumbnails":["https://static.tigerbbs.com/64d7f8b1a0687a6bf124201afc1b1baa"],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1151227836","pubTimestamp":1734707684,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"老虎资讯综合","introduction":"为用户提供金融资讯、行情、数据，旨在帮助投资者理解世界，做投资决策。","home_visible":1,"id":"102","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"summary":"CagriSema减重效果低于预期。","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"zh","relate_stocks":{"AMGN":"安进","VKTX":"Viking Therapeutics, Inc.","NVO":"诺和诺德","LLY":"礼来"},"translate_title":"Novo Nordisk falls, can competitors \"eat enough\"? Eli Lilly, Amgen and other stocks edge higher","themeId":"","isJumpTheme":false,"ttsUrl":"https://static.tigerbbs.com/08f3ddf955a3ce5e861204242450d61d","symbols_score_info":{"AMGN":1.1,"LLY":1.1,"NVO":1.1,"VKTX":1.1},"content_text":"诺和诺德周五公布了一项名为REDEFINE 1的三期临床试验的主要结果。在评估所有人都坚持治疗的治疗效果时，使用CagriSema治疗的患者在68周后体重减轻22.7%，低于市场预期的25%。诺和诺德股价仍跌超19%，跌幅有所收窄。诺和诺德的竞争对手方面，截至发稿礼来涨4.6%，Viking Therapeutics涨3.6%，安进涨超1%。","kind":"news","is_publish_news":true,"is_publish_highlight":true,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0},"commentList":[],"hasMoreComments":false,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false}}